Sensitization is common in pediatric heart transplant candidates and waitlist mortality is high. Transplantation across a positive crossmatch may reduce wait time, but is considered high risk. We prospectively recruited consecutive candidates at eight North American centers. At transplantation, subjects were categorized as nonsensitized or sensitized (presence of ≥1 HLA antibody with MFI ≥1000 using single antigen beads). Sensitized subjects were further classified as complement-dependent cytotoxicity crossmatch (CDC-crossmatch) positive or negative and as donor-specific antibodies (DSA) positive or negative. Immunosuppression was standardized.
| INTRODUC TI ON
Pediatric heart transplant candidates are frequently sensitized to human leukocyte antigens (HLAs), often with broad patterns of sensitization. 1, 2 The optimal strategy for managing these patients is unknown.
Sensitized candidates have traditionally had a high waitlist mortality, 1, 3, 4 and this has led some groups to propose that children with high risk of death on the waitlist should undergo transplantation with the first available organ, without a requirement for a negative virtual or physical donor-specific complement-dependent cytotoxicity (CDC) crossmatch. [5] [6] [7] Such an approach might decrease waitlist mortality but potentially at the price of increased morbidity and mortality in the posttransplant period. 8 To enhance the evidence base for clinical decision making, we developed a prospective, multi-institutional observational cohort study to assess the impact of pretransplant sensitization on pre-and posttransplant outcomes. The central hypothesis is that highly sensitized candidates can achieve first-year outcomes similar to nonsensitized ones in the current era. This will help determine whether transplantation across a positive CDC-crossmatch and donor-specific antibody (DSA) barriers is an acceptable option for selected candidates considered at very high risk for death on the waitlist.
| MATERIAL S AND ME THODS

| Summary of study design
The study was developed within the infrastructure of the National
Institutes of Health (NIH)-sponsored Clinical Trials in Organ
Transplantation in Children (CTOTC) program (www.ctotc.org). Full details of the study design are provided elsewhere 2 and include overall study design, organization and duration, study sites, inclusion and exclusion criteria, subject population, study definitions, sensitization status, primary and secondary endpoints, immunosuppression management, rejection surveillance, study visits with "schedule of events," and details of the various core laboratories. All sites received institutional review board approval and informed consent was obtained from all participants.
| Sensitization status and donorspecific crossmatch
The method for alloantibody testing and determination of pretransplant sensitization status have been previously described. 2 In brief, subjects were considered sensitized when one or more class I and/ or class II HLA antibodies with median fluorescence intensity (MFI) ≥1000 were detected using Luminex LABScreen single antigen beads (One Lambda, Canoga Park, CA). All others were considered nonsensitized. Donor and recipient molecular typing was by low resolution molecular technique (including for HLA-C and -DQ). Donor and recipients were typed for DQB1* and when possible for DQA1*, and for DSA assignment we considered DQB1*/DQA1* pair based on DQA1* typing or DR/DQB1* association. There was variable availability of -DP molecular typing and HLA-DP antibodies were only assessed for DSA status when donor and recipient DP typing were available.
Core laboratory assessment of all pre-and posttransplant samples was performed at the University of Pittsburgh Alloantibody Core by a single technician with interpretation, including DSA designation, by the Core Director (AZ). All posttransplant outcomes in this report are based on sensitization status as determined by the core laboratory.
Results of local single antigen testing at the clinical site were also collected; nonsensitized subjects were designated as Cohort A and patients sensitized to class I and/or class II HLA were designated as Cohort B. In this report, local site sensitization status assignment was used only for analysis of pretransplant outcomes.
At the time of transplant, patients underwent local site T and B cell CDC-XM according to standard of clinical care at each sites' HLA laboratory, which was not modified for the purposes of this observational study. Sites used anti-human globulin augmented CDC-XM with and without dithiothreitol, and with modified Amos method used at three sites as previously described. 2 Of 240 transplanted subjects, a donor-specific CDC-crossmatch result was available in 221 cases. For the remaining 19 subjects, 13 had no DSA by the core laboratory (and with local negative flow crossmatch in 11 of 13). For the purpose of all analyses based on crossmatch results, these subjects were considered as crossmatch negative and included in the analyses. CDC crossmatches were deemed false positive when associated with no DSA (core laboratory). These subjects were excluded from analyses incorporating crossmatch results. Transplantation across a positive virtual crossmatch (VXM) was considered to have occurred when the subject had one or more HLA antibodies with MFI ≥1000 at transplant that were donor specific, as determined by the core laboratory.
| Clinical care guidelines
The standardized immunosuppression protocol is described elsewhere. 2 In brief, all patients received thymoglobulin induction (total antibody-mediated and cellular rejection was lower in the crossmatch positive group and/or in the presence of DSA. Follow-up will determine if acceptable outcomes can be achieved long-term.
K E Y W O R D S
alloantibody, clinical research/practice, crossmatch, heart transplantation/cardiology, pediatrics, rejection: antibody-mediated (ABMR) cumulative dose 7.5 mg/kg) and maintenance immunosuppression with tacrolimus and mycophenolate mofetil. For CDC-crossmatch negative patients, routine maintenance corticosteroids were not given.
CDC-crossmatch positive patients underwent a 1-to 3-fold intraoperative plasma exchange, a 5-day course of posttransplant plasma exchange/plasmapheresis, and a course of intravenous immunoglobulin (IVIG) (2 g/kg given monthly for 6 months). CDC-crossmatch positive subjects also received maintenance corticosteroids for a minimum of 6 months. Subjects with DSA but negative CDC-crossmatch were initially (ie, perioperative period) managed in similar manner to nonsensitized subjects. Subsequent management was adjusted according to the clinical course and rejection findings as outlined in the CTOTC-04 Clinical Care Guidelines. 
| Study endpoints analyzed in this report
The primary endpoint for CTOTC-04 is a composite of the incidence of death, retransplantation, or rejection with hemodynamic compromise at 12 months posttransplant. Secondary endpoints include:
waitlist mortality, individual components of the primary endpoint, acute antibody mediated rejection, cellular rejection, clinical rejection, mixed rejection, infection, rehospitalization, new onset diabetes mellitus, and posttransplant lymphoproliferative disease. All endpoints were analyzed up to 1 year posttransplant for this report.
In addition, we determined the ability of DSA status to predict a positive CDC-crossmatch result.
| Statistical considerations
The primary hypothesis is that the incidence rate at 12 months of the primary composite endpoint is more than 0.20 higher (ie, 0.35 or greater) in the crossmatch positive participants relative to the corresponding expected rate in nonsensitized participants of 0.15.
Power calculations were reported previously. 2 Initial study design was based on estimated accrual of 40 patients with positive CDC-crossmatch.
For the current report, data are summarized using descriptive statistics for categorical (counts and percentages) and continuous confidence intervals are reported. Log-negative-log plots and plots of Schoenfeld residuals were inspected to assure the proportionality assumption was met. All Cox proportional hazard models reported met this assumption. All statistical analyses were performed using SAS Version 9.4 (SAS Institute, Inc., Cary, NC).
| RE SULTS
| Participant characteristics
Of 290 enrolled subjects, 136 (46.9%) were nonsensitized and 154
(53.1%) were sensitized based on local evaluation at the time of listing/enrollment. A total of 240 subjects underwent transplantation during the study period. By local site antibody assessment, 97 (40.4%) of transplanted subjects were nonsensitized (Cohort A) and 143 (59.6%)
were determined to be sensitized (Cohort B) at transplantation. There were 108 (45.6%) nonsensitized and 129 (54.4%) sensitized subjects based on the Alloantibody Core Laboratory (with 3 subjects missing pretransplant samples at the core laboratory) ( Figure 1 ). Three nonsensitized subjects and 6 sensitized subjects were excluded from the analyses comparing crossmatch groups due to either a false positive crossmatch (n = 5) or missing/inconclusive crossmatch data (n = 4).
Overall, 290 subjects (100% of the enrolled cohort) contributed to pretransplant outcomes analyses, 237 to posttransplant outcomes based on core laboratory DSA status, and 228 for posttransplant outcomes analyses based on crossmatch status.
Baseline characteristics of subjects who were sensitized versus not sensitized at transplant have been previously reported.
2
Differences between the characteristics of sensitized subjects, with and without a positive CDC-crossmatch, are shown in Table 1 .
Among sensitized subjects, those with positive CDC-crossmatch were more likely to carry a diagnosis of CHD compared to those with a negative crossmatch (81.8 vs. 47.3%; P = .0842), and were more likely to have prior homograft (54.5 vs. 19.6%; P = .0169). Table S1 for further details). This group was characterized by class I DSA in 4, class II in 2 and both class I and class II in 5 ( Figure 1 ).
More than one DSA was present at transplant in 10/11 (90.9%) CDCcrossmatch positive subjects (median number DSA per subject 3; range 1-7). Median MFI was 15 000 for the DSA with highest MFI value (range 4150-23 600), and median cumulative MFI of all DSA in a given subject was 18 900 (range 5250-100 000). The crossmatch was T and B cell positive in 6 and B cell positive in 5. Median cPRA for these 11 subjects at transplant was 99 (range 52-100) for threshold MFI of ≥1000 and 98 (range 48-100) for ≥8000 MFI. The ability of DSA to predict a positive CDC-crossmatch was evaluated with two different approaches; first using a cutoff of highest DSA MFI of ≥8000, and then with a cumulative DSA MFI of ≥8000. In both approaches the sensitivity of predicting a positive CDC-crossmatch was very poor (56% in both cases), with a specificity of 95% and 94%, respectively (Supplemental Material, Table S2 ).
| Waitlist outcomes
Among the 290 enrolled subjects, a competing risk analysis was performed for the four mutually exclusive outcomes from the time of listing: Died waiting, delisted (all causes), transplanted, and remains on waitlist. Based on local alloantibody testing, pretransplant outcomes were similar among sensitized and nonsensitized candidates ( Figure 2 ). The risk of death on the waitlist between the two groups was not statistically different (P = .6167). However, a slightly higher proportion of nonsensitized candidates achieved transplantation compared to sensitized ones (86.8 vs. 79.2%, P = .0150; Figure 2 ).
The median time to transplant was shorter in Cohort A than Cohort B (57 days vs. 83 days, respectively; P = .0374). Cohort B CDCcrossmatch positive subjects had median wait time of 49 days compared to 87 days for Cohort B CDC-crossmatch negative (P = .4266).
| Primary outcome
Incidence rates of the composite primary endpoint (death, retransplantation or rejection with hemodynamic compromise at 12 months posttransplant) for the three groups were equal to 6.7% (CI: 2.7%, 13.3%), 18.2% (CI: 2.3%, 51.8%) and 10.7% (CI: 5.7%, 18.0%) for nonsensitized, sensitized crossmatch positive, and sensitized crossmatch negative subjects, respectively (P = .2354). Freedom from the primary composite endpoint and its individual components is shown in Figure 3 and a summary of the individual events contributing to the primary endpoint is shown in Table 2 . There were no statistically significant differences between groups for the primary endpoint (P = .2556), nor any of its individual components.
Since the sensitized crossmatch negative group is heterogeneous, including subjects with and without DSA, the primary outcome analysis was repeated using data from the Alloantibody Core 
| Rejection outcomes
Freedom from acute antibody mediated (AMR) and cellular (ACR) rejection were inferior in CDC-crossmatch positive patients (P < .0001
and P = .0095, respectively; Figure 5 ). After adjusting for age, diagnosis, race, and gender for the AMR outcome, group differences TA B L E 1 (Continues) transplantation ( Figure 6 ). Recurrent rejection (two or more episodes)
was more common in CDC-crossmatch positive subjects for both AMR and ACR, with statistical significance for AMR (P < .0001) ( Figure 6 , upper panel). However, less than one-fifth of CDC-crossmatch positive patients experienced recurrent ACR (n = 2) and less than onethird experienced recurrent AMR (n = 3).
F I G U R E 3 Probability of freedom from the primary endpoint (A) and its constituent components (panels B-D) stratified by sensitization and CDC-crossmatch status at transplant. For this (and all subsequent survival curves), the number of participants at risk is presented at selected time points along the x-axis. The number at risk at the start of the observation period (time of transplant) is also shown in the colored figure legend 
| Exploring strategies for defining high risk sensitized populations pretransplantation
There is currently no consensus about the need for CDC-crossmatches for the identification of sensitized candidates at high risk for adverse transplant outcomes. In a preliminary analysis, we evaluated 4 different strategies for assessing patients at high risk for adverse outcomes:
Positive CDC-crossmatch; one or more DSA with MFI ≥8000; cumulative MFI value ≥8000 for all identified DSA; and lastly, presence of any of above (ie, positive CDC-crossmatch, or DSA with MFI ≥8000, or DSA with cumulative MFI ≥8000). For any of these approaches, freedom from the primary composite endpoint was approximately 80% at 1 year posttransplant ( Figure 8A ). Freedom from AMR was also very similar for each strategy with approximately 40%-50% subjects being event-free at 1 year ( Figure 8B ).
F I G U R E 6
Burden of rejection among study group subjects as assessed by proportion of subjects with 0, 1 or 2 or more acute rejection episodes (upper panels) and by average number of rejection episodes per subject (lower panels). Left hand panels show acute antibody mediated rejection (A) and right hand panels, acute cellular rejections (B) 
| Other posttransplant outcomes
Initial posttransplant course, including use of mechanical circulatory support, death during transplant admission, and length of initial hospital stay are shown in Table 3 . There were no statistically significant differences between groups, though median stay for crossmatch positive patients exceeded that for nonsensitized patients by 5 days.
Freedom from first infection associated with hospitalization and/ or use of intravenous antimicrobial therapy (P = .8564) and rehospitalization (P = .6960) did not differ between subject cohorts (Figure 9 ).
Only 3 cases of PTLD were observed (1.3%), with similar freedom from PTLD across all three groups. New onset diabetes mellitus was observed in 7 of 239 (2.9%) subjects (one subject with diabetes pretransplant), with lower freedom from diabetes in the crossmatch positive group (all of whom received maintenance corticosteroids for a minimum of 6 months' posttransplant) (P = .0050; Figure 9 ). 
| D ISCUSS I ON
| The rationale for transplantation across a positive donor-specific crossmatch
Within CTOTC-04, we have demonstrated with single antigen bead testing that approximately 50% to 60% of pediatric heart transplant candidates are sensitized against HLA antigens.
2 Many were sensitized against a broad range of HLA antigens, and in a third of the sensitized subjects, one or more HLA antibodies had an MFI value of ≥8000.
2
The pretransplant assessment of candidates' alloantibody profiles has been widely used to guide donor organ acceptance. Some programs avoid any donor-recipient combination where DSA is identified in the candidate. Such strategies might improve posttransplant outcomes, but at the potential cost of increased wait times and waitlist mortality for sensitized candidates. 1, 3, 4, 11, 12 This may be particularly problematic for infants and young children with congenital heart disease who have traditionally had some of the highest waitlist mortalities (https://optn.transplant.hrsa.gov). 13 The dilemma of Several centers previously demonstrated that transplantation across a positive donor-specific CDC-crossmatch is feasible and can achieve early patient and graft survival similar to that for patients without a positive CDC-crossmatch. [5] [6] [7] However, some groups noted severe early rejection episodes that were difficult to control. 6, 7 Thus, it is unknown if this is an appropriate strategy for select highly sensitized candidates considered to be at high risk for death on the waitlist.
Of note, many of these candidates have forms of CHD that make mechanical support very challenging, so extended waits for a negative crossmatch are generally not possible. CTOTC-04 was designed to extend these preliminary observations to evaluate the safety and efficacy of transplantation across a positive CDC-crossmatch, and across DSA barriers, in a multi-institutional cohort of children listed for heart transplantation.
| Are the results of transplantation against a positive crossmatch acceptable?
In this observational study, where transplantation was permitted against any type of positive crossmatch (including cytotoxicity positive), we have noted that pretransplant outcomes for sensitized and nonsensitized candidates were very similar. This may reflect, at least in part, the decision to accept organs in the face of known DSA, as occurred in 40% of the sensitized candidates in this cohort. These pretransplant outcomes contrast with multiple prior studies demonstrating inferior waitlist survival for sensitized candidates when there is a requirement for a negative prospective crossmatch.
1,3,4
In the posttransplant period, the primary composite endpoint and its individual components did not differ significantly between the study groups during the first year. However, the very small number of positive CDC-crossmatches greatly limits the confidence with which we can draw conclusions, though these observations are comparable to prior single center reports. [5] [6] [7] Nonetheless, 1-year survival (>90%) and freedom from retransplantation (100%) were equal between groups and are superior to other high-risk groups that we routinely transplant (eg, ECMO and failed Fontan patients).
When we analyzed the primary endpoint with the more robust data- ECMO given posttransplant, n (%) 7 (6.7) 11 (9.8) 1 (9.1)
(8.3)
.5918
Death prior to transplant hospitalization discharge, n (%) rejection with hemodynamic compromise was very rare in all groups, which contrasts with earlier single center reports. 6, 7 By contrast, freedom from AMR and ACR was inferior in the CDC-crossmatch positive group, and recurrent rejection (particularly AMR) was also more common in the CDC-positive cohort.
However, it is important to note that less than one-third of the CDC- 
26
Progress in predictive modeling is most advanced for adult renal transplantation, where detailed characterization of DSA may provide sufficient information, when combined with clinical characteristics, to allow accurate prediction of AMR and graft outcomes.
21,22
Although such studies were outside the scope of this initial report, we are pursuing similar approaches within an expanded cohort of pediatric heart transplant subjects.
| Study limitations
The most elegant study design would have been a randomized controlled trial, randomizing highly sensitized candidates to a strategy of waiting for a negative crossmatch versus transplanting with the first suitably sized and functioning organ without regard to DSA status. We did not believe that such a design would be feasible. A further limitation is that we did not track the institutional response to each donor organ offer, so we cannot quantify physician behavior as it pertains to donor acceptance for highly sensitized candidates.
We also did not randomize crossmatch positive patients to different treatment regimens, since it was not the goal of this study to compare different management strategies for crossmatch positive patients. Such studies are needed but are not likely feasible in the pediatric heart population due to small numbers. We did, however, achieve standardized clinical care including immunosuppression based on current agreed best practices. This greatly enhances the value of our data.
We enrolled fewer patients than originally planned, and the number of patients with a positive CDC-crossmatch was also far lower than anticipated. This will inevitably affect the power to detect differences in outcomes between groups, as discussed above. It was also not possible to standardize CDC assays across clinical sites. The high false positive rate for CDC crossmatches mirrored prior studies 11, 12 and argues in favor of designing studies based on DSA and their properties rather than on cytotoxicity assays. In this regard, the greatest value of our study may lie in our observations of outcomes based on DSA findings and not on CDC-crossmatch results. As we follow our cohorts long-term, these observations should help inform virtual crossmatch strategies, the management of sensitized recipients, and will allow for improved patient and family counseling. Our data certainly suggest that a more aggressive approach should be taken to the peri-and postoperative management of candidates with DSA above certain thresholds, independent of CDC-crossmatch result.
This study focuses on short-term (1 year) outcomes. Obviously, longer-term follow-up is required to assess the true impact of pretransplant DSA on pediatric heart transplant outcomes. There is evidence that DSA and positive crossmatch are associated with increased risks of allograft coronary disease and late graft dysfunction and loss. 1, 8, 13, 27 We are currently following this cohort long-term for late clinical events, echocardiographic evaluation of graft function, invasive hemodynamic outcomes, and for angiographic assessment of graft vasculopathy.
| CON CLUS ION
Pediatric heart transplantation across a positive CDC-crossmatch, and in the presence of pretransplant DSA, is associated with acceptable first year graft and patient survival, although AMR rates are high and correlate with higher DSA strength. At this time, it is premature to state that transplantation in these settings is safe and effective. However, the early graft and patient survival and low rates of rejection with hemodynamic compromise described in this study support further ongoing evaluation of transplantation in the setting of preformed DSA among select pediatric heart candidates consid- 
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